A Transendocytosis Perspective on the CD28/CTLA-4 Pathway

被引:28
|
作者
Soskic, Blagoje [1 ]
Qureshi, Omar S. [2 ]
Hou, Tiezheng [3 ]
Sansom, David M. [3 ]
机构
[1] Univ Birmingham, Sch Immun & Infect, Birmingham, W Midlands, England
[2] UCB, Slough, Berks, England
[3] UCL Inst Immun & Transplantat, Royal Free Campus, London, England
来源
基金
英国生物技术与生命科学研究理事会;
关键词
REGULATORY T-CELLS; ANTIGEN-PRESENTING CELLS; MULTIORGAN TISSUE DESTRUCTION; FUNCTION IN-VIVO; DENDRITIC CELLS; PHOSPHATIDYLINOSITOL; 3-KINASE; IMMUNOLOGICAL SYNAPSE; CD28; COSTIMULATION; SURFACE EXPRESSION; CUTTING EDGE;
D O I
10.1016/B978-0-12-800147-9.00004-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cell activation is a key event in the adaptive immune response and vital to the generation of both cellular and humoral immunity. Activation is required not only for effective CD4 T cell responses but also to provide help for B cells and the generation of cytotoxic T cell responses. Unsurprisingly, impaired T cell activation results in infectious pathology, whereas dysregulated activation can result in autoimmunity. The decision to activate is therefore tightly regulated and the CD28/CTLA-4 pathway represents this apical decision point at the molecular level. In particular, CTLA-4 (CD152) is an essential checkpoint control for autoimmunity; however, the molecular mechanism(s) by which CTLA-4 achieves its regulatory function are not well understood, especially how it functionally intersects with the CD28 pathway. In this chapter, we review the established molecular and cellular concepts relating to CD28 and CTLA-4 biology, and attempt to integrate these by discussing the transendocytosis of ligands as a new model of CTLA-4 function.
引用
收藏
页码:95 / +
页数:16
相关论文
共 50 条
  • [21] CD28/CTLA-4 and CD80/CD86 familiesSignaling and function
    Jacqueline M. Slavik
    Jill E. Hutchcroft
    Barbara E. Bierer
    Immunologic Research, 1999, 19 : 1 - 24
  • [22] CD28/CTLA-4及其配体的研究进展
    刘慧萍
    张远强
    李恩善
    解剖科学进展, 1997, (01) : 62 - 66
  • [23] Association of CD28 and CTLA-4 gene polymorphisms with aggressive periodontitis in Brazilians
    Silva, M. R. M. A. e
    Moreira, P. R.
    da Costa, G. C.
    Saraiva, A. M.
    de Souza, P. E. A.
    Amormino, S. A. F.
    da Costa, J. E.
    Gollob, K. J.
    Dutra, W. O.
    ORAL DISEASES, 2013, 19 (06) : 568 - 576
  • [24] A NOVEL FULLY HUMAN CD28 ANTIBODY THAT CROSSREACTS WITH CTLA-4 AND MOUSE CD28 FOR POTENTIAL APPLICATIONS IN CANCER IMMUNOTHERAPY
    Elsayed, Abdullah
    Peissert, Frederik
    Pluss, Louis
    Ulrich, Franziska
    Puca, Emanuele
    De Luca, Roberto
    Halin, Cornelia
    Neri, Dario
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1116 - A1116
  • [25] CTLA-4 augments internalization and degradation of CD28 in CD8+T cells
    Berg, M
    Zavazava, N
    FASEB JOURNAL, 2005, 19 (04): : A908 - A908
  • [26] Is the Genetic Background of Co-Stimulatory CD28/CTLA-4 Pathway the Risk Factor for Prostate Cancer?
    Karabon, Lidia
    Tupikowski, K.
    Tomkiewicz, A.
    Partyka, A.
    Pawlak-Adamska, E.
    Wojciechowski, A.
    Kolodziej, A.
    Dembowski, J.
    Zdrojowy, R.
    Frydecka, I.
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (04) : 837 - 843
  • [27] CD28/CTLA-4 and CD80/CD86 families - Signaling and function
    Slavik, JM
    Hutchcroft, JE
    Bierer, BE
    IMMUNOLOGIC RESEARCH, 1999, 19 (01) : 1 - 24
  • [28] Co-expression of CD28 and CTLA-4 reveals that the extracellular domain of CD28 is sufficient to costimulate IL-2 production, while inhibition is mediated by the CTLA-4 cytoplasmic region
    Hueber, AJ
    Manger, B
    Kalden, JR
    Nagel, T
    FASEB JOURNAL, 2002, 16 (04): : A711 - A711
  • [29] Regulation der T-Zell-Aktivierung über CD28 und CTLA-4Regulation of T-Cell activation by CD28 and CTLA-4
    Thomas Nagel
    Joachim R. Kalden
    Bernhard Manger
    Medizinische Klinik, 1998, 93 : 592 - 597
  • [30] CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation
    Krummel, Matthew F.
    Allison, James P.
    JOURNAL OF IMMUNOLOGY, 2011, 187 (07): : 3459 - 3465